Sector News

Allergan to sell a quarter of its Teva stake in first quarter of 2018

November 14, 2017
Life sciences

Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel’s Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker.

Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a JP Morgan Chase and Co (JPM.N) unit – acting as a dealer for the shares – sometime next quarter. The JP Morgan unit will pay a price based on the average trading price over a yet-to-be determined period before the sale.

Allergan sold its generics business to Teva in August 2016 for $33 billion in cash and 100 million shares of the Israeli generic drugmaker, worth around $5.3 billion at the time.

Under the terms of the deal, Allergan had to hold the shares for at least one year. That has turned out to be a costly agreement for the drugmaker, as Teva’s shares have lost more than three-fourths of their value since the deal.

Allergan’s shares have lost around a third of their value over that period.

Allergan said on Nov. 1 that it planned to begin selling its Teva stake, and this was the first announced sale of the stock.

Two of Israel’s leading financial news outlets reported later that week that billionaire businessman Len Blavatnik was looking to buy a significant stake in debt-ridden Teva, possibly through a deal with Allergan.

It was not clear who the ultimate buyer of Allergan’s shares will be in the JP Morgan transaction.

In the same filing, Allergan said it had taken a margin loan from JP Morgan on its whole 100 million-share stake in Teva.

It did not say how much it was borrowing against the shares, but said it planned to use proceeds from the loan to finance the buyback of 2019 bonds.

By Michael Erman

Source: Reuters

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).